EA201892448A1 - Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения - Google Patents

Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Info

Publication number
EA201892448A1
EA201892448A1 EA201892448A EA201892448A EA201892448A1 EA 201892448 A1 EA201892448 A1 EA 201892448A1 EA 201892448 A EA201892448 A EA 201892448A EA 201892448 A EA201892448 A EA 201892448A EA 201892448 A1 EA201892448 A1 EA 201892448A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic compositions
alkyn
related application
application methods
containing nucleotide
Prior art date
Application number
EA201892448A
Other languages
English (en)
Inventor
Грегори Блумлинг
Абель Де Ла Роза
Джордж Пэйнтер
Дамьен Купер
Александр Колыхалов
Original Assignee
Эмори Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити filed Critical Эмори Юниверсити
Publication of EA201892448A1 publication Critical patent/EA201892448A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к нуклеотидным и нуклеозидным терапевтическим композициям и способам применения при лечении инфекционных заболеваний, вирусных инфекций и рака, причем основание нуклеотида или нуклеозида содержит по меньшей мере один тиол, тион или тиоэфир.
EA201892448A 2016-04-28 2017-04-28 Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения EA201892448A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328857P 2016-04-28 2016-04-28
PCT/US2017/030080 WO2017189978A1 (en) 2016-04-28 2017-04-28 Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Publications (1)

Publication Number Publication Date
EA201892448A1 true EA201892448A1 (ru) 2019-06-28

Family

ID=60160145

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892448A EA201892448A1 (ru) 2016-04-28 2017-04-28 Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Country Status (7)

Country Link
US (2) US11192914B2 (ru)
EP (1) EP3448392A4 (ru)
JP (3) JP7129703B2 (ru)
CN (1) CN109689063A (ru)
CA (1) CA3022119A1 (ru)
EA (1) EA201892448A1 (ru)
WO (1) WO2017189978A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209425A1 (en) * 2020-04-14 2021-10-21 Janssen Sciences Ireland Unlimited Company Alkynyl nucleoside analogs for treatment of hepatitis e
US11357865B2 (en) 2020-04-27 2022-06-14 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113621013B (zh) * 2021-09-17 2023-07-21 中国人民解放军军事科学院军事医学研究院 2`-乙炔基腺苷磷酰胺类衍生物及其制备方法和用途
CN117567310A (zh) * 2023-11-28 2024-02-20 重庆智合生物医药有限公司 一种神经酰胺np1的合成方法

Family Cites Families (442)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607925A (en) 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
UA6419A1 (ru) 1991-01-03 1994-12-29 Чеслав-Констянтин Альбінович Будревич Ветродвигатель будревича
EP0627930A4 (en) 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
GB9605293D0 (en) 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AU5157998A (en) 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6010890A (en) 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6103706A (en) 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6143752A (en) 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
JP3838034B2 (ja) 1997-10-13 2006-10-25 大塚製薬株式会社 Ｃ型肝炎治療効果の改善剤及びその応用
FR2771637B1 (fr) 1997-12-01 2003-10-24 Hutchinson Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
CA2313049A1 (en) 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
EP1053243B1 (en) 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
CA2326535A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP2000007578A (ja) 1998-06-24 2000-01-11 Hiroaki Okushin Ｃ型肝炎ウイルスの陰性化のための投薬システム
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
RU2158604C2 (ru) 1998-07-03 2000-11-10 Толоконская Наталья Петровна Способ лечения вирусного гепатита c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1121369B1 (en) 1998-10-16 2004-12-08 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CA2354536A1 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037097A1 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
JP2000212099A (ja) 1999-01-19 2000-08-02 Mochida Pharmaceut Co Ltd ウイルス性肝炎治療剤
DE60017243T2 (de) 1999-02-13 2005-12-08 Purepulse Technologies, Inc., San Diego Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
JP2002541204A (ja) 1999-04-12 2002-12-03 ユニバーシティ オブ マドラス Ｂ型肝炎、ｃ型肝炎及びその他の肝臓の関連ウイルス感染の治療に有用な医薬製剤及びその調製方法
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
JP2003507339A (ja) 1999-08-13 2003-02-25 エフ．ホフマン−ラ ロシュ アーゲー ＰＥＧ−ＩＦＮ−αと共同させたミコフェノラートモフェチル
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR100392292B1 (ko) 2000-01-07 2003-07-22 주식회사 펩트론 5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
AU764095B2 (en) 2000-04-07 2003-08-07 Shionogi & Co., Ltd. Preincubation assay method
CA2406140A1 (en) 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
US6415797B1 (en) 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CZ303213B6 (cs) 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
KR20030043924A (ko) 2000-08-02 2003-06-02 오르토-맥네일 파마슈티칼, 인코퍼레이티드 에리트로포이에틴 투여에 의한 개선된 항-바이러스 및항-종양 화학 요법
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PT1326632E (pt) 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
IL155414A0 (en) 2000-10-13 2003-11-23 Univ Monash Disease prevention by reactivation of the thymus
MXPA03003456A (es) 2000-10-18 2003-07-14 Schering Corp Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.
FR2815543B1 (fr) 2000-10-19 2003-10-24 Sedat Seringue d'auto-injection d'un melange extemporane
JP2004537500A (ja) 2000-10-20 2004-12-16 ジェネティクス インスティテュート，エルエルシー 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
JP2004513136A (ja) 2000-11-08 2004-04-30 スリル　バイオメディカル　コーポレーション 抗癌剤として有用な新規ポリアミンアナログ−アミノ酸結合体
AU2002245081A1 (en) 2000-12-06 2002-07-16 The Trustees Of The University Of Pennsylvania Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6833351B2 (en) 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
CN1522159A (zh) 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
CA2453475A1 (en) 2001-07-20 2003-01-30 Intermune, Inc. Methods of treating liver fibrosis
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
HUP0401659A3 (en) 2001-09-28 2005-02-28 Intermune Inc Brisbane Method for treating hepatitis c virus infection in treatment failure patients
PL369129A1 (en) 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CN1738635A (zh) 2001-10-05 2006-02-22 印特缪恩股份有限公司 用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
AR037131A1 (es) 2001-10-31 2004-10-20 Schering Corp Formulaciones de jarabe de ribavirina
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002346686A1 (en) 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
US6906190B2 (en) 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
RU2212248C1 (ru) 2002-01-21 2003-09-20 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения больных хроническим вирусным гепатитом c
CA2476896A1 (en) 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
CA2383243A1 (en) 2002-04-23 2003-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for inhibiting fibrogenesis
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040034206A1 (en) 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
ITMI20021860A1 (it) 2002-08-28 2004-02-29 Scalia Antonio Cassar Impiego dei triptani come agenti antivirali.
EP1556498A1 (en) 2002-11-01 2005-07-27 Cadila Healthcare Ltd. Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
AU2003295773A1 (en) 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
JP2006517960A (ja) 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
WO2004078127A2 (en) 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2005016288A2 (en) 2003-02-28 2005-02-24 Intermune, Inc. Methods and compositions for treatment of viral diseases
TWI269656B (en) 2003-03-05 2007-01-01 Original Image Co Ltd Therapeutical composition for hepatitis C
US20040198840A1 (en) 2003-04-02 2004-10-07 Deloach Reuben Edwin Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
PE20050204A1 (es) 2003-05-21 2005-05-04 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
EP2345659A1 (en) * 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US20050187170A1 (en) 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
EP1643981A2 (en) 2003-06-20 2006-04-12 Viral Genomix, Inc. Antiviral compositions and methods of using the same
AU2004260009A1 (en) 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
MD2549G2 (ru) 2003-07-18 2005-08-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Метод лечения хронического вирусного гепатита С
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
AP2006003542A0 (en) 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
EP1671643A1 (en) 2003-09-08 2006-06-21 Intellectual Property Consulting Inc. Medicinal composition for treating chronic hepatitis c
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20050085528A1 (en) 2003-10-17 2005-04-21 Pfizer Inc. Parmaceutical
NZ546873A (en) 2003-10-24 2010-09-30 Immunaid Pty Ltd Method of analysing immune system cycling to monitor and/or treat diseases characterised by the production of regulator T cells
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
PT1677827E (pt) 2003-10-27 2009-03-13 Vertex Pharma Associações para o tratamento do vhc
UA68233A (en) 2003-11-25 2004-07-15 Univ Zaporizhia State Medical Method for treating chronic hepatitis c
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
US7648998B2 (en) 2003-12-22 2010-01-19 K.U. Leuven Research & Development Imidazo 4,5-c pyridine compounds and methods of antiviral treatment
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2005067454A2 (en) 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection
WO2005062949A2 (en) 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
DE10361944A1 (de) 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
US7205330B2 (en) 2004-02-27 2007-04-17 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
AR048832A1 (es) 2004-04-22 2006-05-31 Smith Howard J & Ass Pty Ltd Tratamiento de soporte de enfermedades hepaticas
JP4943322B2 (ja) 2004-05-04 2012-05-30 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 標的細胞中のウイルスゲノム量を減少させるための方法および組成物
EP1747233A4 (en) 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
KR101370580B1 (ko) 2004-06-08 2014-03-06 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
ATE497775T1 (de) 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1627641A1 (en) 2004-08-04 2006-02-22 Victor Eluwa Pharmaceutical compositions comprising metal oxides and uses thereof
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US20100041617A1 (en) 2004-09-27 2010-02-18 Jane Trepel Modulating mxa expression
CA2580448C (en) 2004-10-01 2012-09-18 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
EP1804821A4 (en) 2004-10-01 2009-07-15 Vertex Pharma INHIBITION OF HCV NS3-NS4A PROTEASE
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
US20060228333A1 (en) 2004-10-20 2006-10-12 Kye-Hyung Paik Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20060105063A1 (en) 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
BRPI0606647A2 (pt) 2005-01-17 2009-07-14 Jerini Ag antagonistas do receptor de c5a
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
WO2006089113A2 (en) 2005-02-18 2006-08-24 Intermune, Inc. Biomarkers for predicting liver fibrosis treatment efficacy
WO2006091610A2 (en) 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US20070003608A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006113431A2 (en) 2005-04-13 2006-10-26 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
SG161315A1 (en) 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
EP1881828A4 (en) 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
WO2006127482A1 (en) 2005-05-20 2006-11-30 Bioenvision, Inc. Methylene blue therapy of viral disease
AU2006250068A1 (en) 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
CA2608709A1 (en) 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
US7793040B2 (en) 2005-06-01 2010-09-07 Microsoft Corporation Content addressable memory architecture
WO2006130688A2 (en) 2005-06-02 2006-12-07 Schering Corporation Compounds for inhibiting cathepsin activity
US20070207949A1 (en) 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
JP5160415B2 (ja) 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション 医薬処方物およびそれを用いる治療方法
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130553A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20070232527A1 (en) 2005-06-02 2007-10-04 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
BRPI0613796A2 (pt) 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
RU2293572C1 (ru) 2005-07-18 2007-02-20 Гюнтер Хаазе Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP2402331A1 (en) 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
BRPI0614761A2 (pt) 2005-08-12 2009-05-19 Human Genome Sciences Inc proteìnas de fusão de albumina
DE102005038768A1 (de) 2005-08-16 2007-02-22 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Borreliose
EP2357170A1 (en) 2005-08-19 2011-08-17 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2007030560A2 (en) 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
US7531164B2 (en) 2005-10-21 2009-05-12 Duke University Preventing bacterial or viral infectivity and composition containing infection preventing additive
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
RU2306134C2 (ru) 2005-11-07 2007-09-20 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ базисного лечения хронического вирусного гепатита c
KR20080072906A (ko) 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
RU2326115C2 (ru) 2005-11-21 2008-06-10 Ефаг АО Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2632903C (en) 2005-12-02 2015-11-24 Vianova Labs, Inc. Treatment of cancer and other diseases
WO2007065829A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Antiviral nucleosides
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
RU2306934C1 (ru) 2005-12-28 2007-09-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ лечения больных хроническим вирусным гепатитом c
DK1976516T3 (da) 2006-01-09 2013-07-15 Romark Lab Lc Behandling af viral hepatitis
MD20060037A (ru) 2006-01-24 2007-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Метод лечения острого вирусного гепатита С
TW200808308A (en) 2006-02-09 2008-02-16 Schering Corp Novel HCV inhibitor combinations and methods
EP1981524A2 (en) 2006-02-09 2008-10-22 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
WO2007098270A2 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
CA2646335A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CN101494979A (zh) 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
WO2007130646A2 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
US20100256217A1 (en) 2006-05-22 2010-10-07 The Trustees Of The University Of Pennsylvania Antiviral inhibition of casein kinase ii
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US20080241869A1 (en) 2006-06-02 2008-10-02 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
GB2453068B (en) 2006-06-04 2011-03-09 Cellartis Ab Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2007149382A2 (en) 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20080081791A1 (en) 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
EA018098B1 (ru) 2006-07-07 2013-05-30 Джилид Сайэнс, Инк. Фосфинатные соединения (варианты)
AU2007272839B2 (en) 2006-07-13 2012-05-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
EP2054076A2 (en) 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
AU2007286754A1 (en) 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2008073165A2 (en) 2006-08-25 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
EP2068905A4 (en) 2006-09-14 2009-12-30 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
CA2666098C (en) 2006-10-10 2012-09-25 Steven D. Axt Preparation of nucleosides ribofuranosyl pyrimidines
US7777395B2 (en) 2006-10-12 2010-08-17 Eastman Kodak Company Continuous drop emitter with reduced stimulation crosstalk
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
PL2104674T3 (pl) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Canada Incorporated Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
US20100093824A1 (en) 2006-11-29 2010-04-15 Judith Frydman Methods of treating viral infection
MX2009006056A (es) 2006-12-07 2009-06-16 Schering Corp Formulacion de matriz sensible al ph.
RU2336096C1 (ru) 2006-12-14 2008-10-20 ООО Медицинский центр "Столица" Способ лечения гепатита с
RU2345787C2 (ru) 2006-12-25 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ лечения хронического вирусного гепатита с
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2111227A1 (en) 2007-01-08 2009-10-28 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
CL2008000321A1 (es) 2007-02-01 2008-08-22 Tibotec Pharm Ltd Compuesto macrociclo en forma cristalina, inhibidor del virus de la hepatitis c (vhc); mezcla de una o mas formas cristalinas; procesos de preparacion de las formas cristalinas; y composicion farmaceutica que las comprende.
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US8222239B2 (en) 2007-02-21 2012-07-17 Allaccem, Inc. Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
JP2010519330A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
MD3477G2 (ru) 2007-03-21 2008-08-31 Николае БОДРУГ Метод лечения хронического вирусного гепатита С
WO2008116194A2 (en) 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
US20100129437A1 (en) 2007-03-23 2010-05-27 Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
US20080269205A1 (en) 2007-04-27 2008-10-30 Ondine International, Ltd. Methods to prevent vertical transmission of infectious diseases
JP2010525063A (ja) 2007-04-27 2010-07-22 キメリクス，インコーポレイテッド ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
CA2686138A1 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
AR066528A1 (es) 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
JP2010528013A (ja) 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン
RU2348412C1 (ru) 2007-06-01 2009-03-10 Лариса Леонидовна Попова Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
WO2008154248A1 (en) 2007-06-06 2008-12-18 Inova Health System Prognostic chronic hepatitis c biomarkers
US8178491B2 (en) 2007-06-29 2012-05-15 Gilead Sciences, Inc. Antiviral compounds
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US8137661B2 (en) 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
JP2010534530A (ja) 2007-07-26 2010-11-11 エントラ ファーマシューティカルズ，インコーポレイテッド 薬物を供給するためのシステム及び方法
BR122020008558B1 (pt) 2007-08-03 2021-11-03 Biotron Limited Composição, e, uso de uma composição
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
WO2009033183A2 (en) 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
US20090076100A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched gsk625433
WO2009038663A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
CN102746240B (zh) 2007-09-17 2017-10-03 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
RU2542099C2 (ru) 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
CA2976793A1 (en) 2007-09-17 2009-03-26 Abbvie Ireland Unlimited Company Uracil or thymine derivative for treating hepatitis c
WO2009039248A2 (en) 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090082414A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
CA2701190C (en) 2007-10-03 2017-12-05 Sabell Corporation Herbal compositions and methods for treating hepatic disorders
EP2211895A2 (en) 2007-10-05 2010-08-04 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
JP2011503060A (ja) 2007-11-05 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０、ｐｅｇ−ｉｆｎおよびリババリンを含むｈｃｖ併用治療剤
US20110182858A1 (en) 2007-11-15 2011-07-28 Madaus Gmbh Silibinin component for the treatment of hepatitis
BRPI0820733A2 (pt) 2007-12-21 2015-06-16 Hoffmann La Roche Processo para a preparação de macrociclo
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US20100298256A1 (en) 2007-12-27 2010-11-25 Steven Dong Antiviral compounds
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
JP5283106B2 (ja) 2008-03-14 2013-09-04 国立大学法人 熊本大学 Ｃ型肝炎ウイルス阻害剤
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110045001A1 (en) 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
EP2283002A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CN102083433A (zh) 2008-04-23 2011-06-01 弗特克斯药品有限公司 用替拉瑞韦(VX-950)治疗对聚乙二醇化干扰素α-2A/2B和利巴韦林治疗无应答患者的丙型肝炎病毒感染
DE102008029669A1 (de) 2008-05-16 2009-11-19 Schlaak, Jörg Friedrich, Prof. Dr. med. Neue Therapeutika für die Hepatitis-Therapie
US20110218512A1 (en) 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
JP2011522834A (ja) 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用
BRPI0915109A2 (pt) 2008-06-10 2016-02-10 Janssen Pharmaceutica Nv regime de dosagem do telaprevir
EP2349257B1 (en) 2008-06-17 2013-11-27 Universidade Federal de Minas Gerais-UFMG Use of paf receptor for treating infections caused by flaviviridae
SI2540350T1 (sl) 2008-07-22 2015-01-30 Merck Sharp & Dohme Corp. Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami
WO2010011343A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
RU2373952C1 (ru) 2008-07-30 2009-11-27 Юрий Михайлович Амбалов Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
WO2010017178A1 (en) 2008-08-06 2010-02-11 Sciclone Pharmaceuticals, Inc. Treatment or prevention of hepatitis c with immunomodulator compounds
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
WO2010015545A1 (en) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
AR072991A1 (es) 2008-08-07 2010-10-06 Schering Corp Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010020676A1 (en) 2008-08-20 2010-02-25 Vib Vzw The use of topoisomerase type i inhibitors to treat viral infections
JP2012501345A (ja) 2008-08-28 2012-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖ遺伝子型の分析
CN102137682B (zh) 2008-08-29 2014-07-02 国立大学法人大阪大学 抗丙型肝炎病毒组合物
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
BRPI0918513A2 (pt) 2008-09-16 2015-12-01 Boehringer Ingelheim Int formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso
EA019965B1 (ru) 2008-09-17 2014-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
CA2738477A1 (en) 2008-09-24 2010-04-01 Robert S. Kauffman Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis
US8759010B2 (en) 2008-09-26 2014-06-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Host cell kinases as targets for antiviral therapies against HCV infection
JPWO2010038796A1 (ja) 2008-09-30 2012-03-01 持田製薬株式会社 Ｃ型肝炎治療剤
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
CN102257140A (zh) 2008-10-08 2011-11-23 夏洛特-梅克伦堡医院管理局D/B/A卡罗莱纳医学中心 用微rna-196的过表达治疗丙型肝炎病毒感染
JP2012505897A (ja) 2008-10-15 2012-03-08 インターミューン・インコーポレーテッド 治療用抗ウイルス性ペプチド
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
EP2358439A1 (en) 2008-11-05 2011-08-24 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
ES2445516T3 (es) 2008-11-21 2014-03-03 Boehringer Ingelheim International Gmbh Composición farmacéutica de un potente inhibidor de HCV para su administración oral
WO2010068760A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP2356236B1 (en) 2008-12-11 2015-07-29 Xiangxue Group (Hong Kong) Company Limited siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
EP2379745A1 (en) 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Biomarkers for hcv treatment response
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2808402A3 (en) 2008-12-29 2015-03-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment
US8840934B2 (en) 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
AU2010203416C1 (en) 2009-01-09 2013-07-25 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
RU2398582C1 (ru) 2009-01-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101649A2 (en) 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
RU2571662C2 (ru) 2009-03-25 2015-12-20 Эббви Инк. Противовирусные соединения и их применения
US8741914B2 (en) 2009-03-25 2014-06-03 Abbvie Inc. Antiviral compounds and uses thereof
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
TWI468160B (zh) 2009-04-25 2015-01-11 Hoffmann La Roche 增進藥物動力學之方法
JP5582662B2 (ja) 2009-05-13 2014-09-03 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP5469744B2 (ja) 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
ES2565536T3 (es) 2009-06-11 2016-04-05 Abbvie Bahamas Ltd. Heterociclos trisustituidos como inhibidores de la replicación del virus de la Hepatitis C VHC
TW201105323A (en) 2009-06-23 2011-02-16 Gilead Sciences Inc Pharmaceutical compositions useful for treating HCV
UY32715A (es) 2009-06-23 2011-01-31 Gilead Sciences Inc Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
US20100324059A1 (en) 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
AU2010264479B2 (en) 2009-06-26 2017-06-01 Romark Laboratories L.C. Compounds and methods for treating influenza
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
DK2451438T3 (da) 2009-07-07 2014-03-10 Boehringer Ingelheim Int Farmaceutisk sammensætning til en hepatitis C-virus-roteaseinhibitor
RU2400229C1 (ru) 2009-07-13 2010-09-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
JP2013500713A (ja) 2009-07-31 2013-01-10 サントル オスピタリエ ウニヴェルシテール ヴォドア Ｈｃｖ感染患者においてｃ型肝炎の転帰を診断又は予測する方法
JP5789260B2 (ja) 2009-08-27 2015-10-07 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスのプロテアーゼ阻害薬の調製方法
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9174988B2 (en) 2009-10-27 2015-11-03 Trustees Of Boston University Small molecule inhibitors of hepatitis C virus
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
AU2010325065A1 (en) 2009-11-09 2012-05-24 Merck Sharp & Dohme Corp. Markers associated with ribavirin-induced anemia
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
JP5536229B2 (ja) 2009-12-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ併用療法
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
RU2424794C1 (ru) 2009-12-30 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) Способ лечения врожденного гепатита с у детей первого года жизни
AU2011210795A1 (en) 2010-01-29 2012-08-02 Vertex Pharmaceuticals Incorporated Therapies for treating Hepatitis C virus infection
CN104771364B (zh) 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CN104017020B (zh) 2010-03-31 2017-04-12 吉利德制药有限责任公司 核苷氨基磷酸酯
TW201211046A (en) 2010-06-07 2012-03-16 Enanta Pharm Inc Macrocyclic hepatitis C serine protease inhibitors
UY33445A (es) 2010-06-10 2012-01-31 Gilead Sciences Inc Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2745102A1 (en) 2010-06-29 2011-12-29 Medicorp Institute Of Canada Pharmaceutical composition and method of use to improve organ function
RU2429877C1 (ru) 2010-06-30 2011-09-27 Общество с ограниченной ответственностью "ИНГИЛС" Способ лечения хронического вирусного гепатита с
WO2012009503A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
JP5819959B2 (ja) 2010-07-16 2015-11-24 アッヴィ・バハマズ・リミテッド 抗ウイルス性化合物を調製するための方法
CN103108651A (zh) 2010-07-30 2013-05-15 默沙东公司 Cyp3a药物代谢的抑制
US20120196272A1 (en) 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
KR20130110170A (ko) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
AU2011314170A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Polycyclic Heterocycle Derivatives and methods of use thereof for the treatment of viral diseases
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
TWI451439B (zh) 2010-12-10 2014-09-01 Phison Electronics Corp 記憶體儲存裝置、其記憶體控制器與資料寫入方法
WO2012083164A1 (en) 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012083170A1 (en) 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
CA2832818A1 (en) 2011-04-06 2012-10-11 The Trustees Of Princeton University Anti-viral combination therapy
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
US20140213632A1 (en) 2011-06-30 2014-07-31 Stella Aps HCV Combination Therapy
US20140113958A1 (en) 2011-06-30 2014-04-24 Stella Aps HCV Combination Therapy
WO2013025975A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
SG2014010490A (en) 2011-08-24 2014-04-28 Glaxosmithkline Llc Combination treatments for hepatitis c
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
US8575119B2 (en) * 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
RU2014122154A (ru) 2011-10-31 2015-12-10 Мерк Шарп И Доум Корп. Композиции, пригодные для лечения вирусных заболеваний
US20130137084A1 (en) 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8980865B2 (en) * 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
JP2015528513A (ja) 2012-09-18 2015-09-28 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための方法
LT2897611T (lt) 2012-09-18 2019-12-10 Abbvie Inc Hepatito c gydymo būdai
WO2014078463A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
CA2894541A1 (en) * 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2865402T3 (es) * 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
HUE036069T2 (hu) 2013-03-14 2018-06-28 Abbvie Inc Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére
EP3213750B1 (en) 2013-03-14 2020-08-12 AbbVie Inc. Combination of two antivirals for treating hepatitis c
US9815864B2 (en) * 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015048744A2 (en) * 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602595TA (en) * 2013-10-11 2016-04-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3082808A1 (en) 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
LT3160476T (lt) * 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
AU2015280234B2 (en) * 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US9980865B2 (en) * 2015-03-30 2018-05-29 Christopher Miranda Elevating wheelchair

Also Published As

Publication number Publication date
EP3448392A1 (en) 2019-03-06
US20190144484A1 (en) 2019-05-16
JP2022106920A (ja) 2022-07-20
US20230062181A1 (en) 2023-03-02
JP2024038012A (ja) 2024-03-19
WO2017189978A1 (en) 2017-11-02
EP3448392A4 (en) 2020-01-15
JP7129703B2 (ja) 2022-09-02
CA3022119A1 (en) 2017-11-02
CN109689063A (zh) 2019-04-26
JP2019515930A (ja) 2019-06-13
US11192914B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2019012233A (es) Anticuerpos anti-sirpa.
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
EA201890494A1 (ru) Способы лечения вирусных инфекций arenaviridae и coronaviridae
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201892448A1 (ru) Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2022007522A (es) Anticuerpos anti-cd27.
UY35732A (es) Composiciones terapéuticas de nucleótidos y nucleósidos y usos relacionados con las mismas
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
GEP20237457B (en) Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов